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Objectives. The aim of this study was to compare the salivary epidermal growth factor (EGF) levels between patients with oral
leukoplakia (OL) and clinically healthy individuals, to evaluate the association between salivary and tissular EGF, and to
correlate EGF with clinicopathologic data, including the presence of dysplasia.
Study Design. Salivary EGF levels were measured in 32 patients and 32 controls. The tissue expressions of EGF and its
receptor (EGFR) were immunohistochemically evaluated.
Results. Salivary EGF levels were similar in patients with OL compared with controls. There was no association between the
salivary levels and immunohistochemical expression of EGF. An absence of EGF detection by immunohistochemistry was
associated with development of multiple lesions. Dysplastic lesions showed a tendency toward presenting higher salivary EGF
levels.
Conclusions. Currently, it is not possible to indicate salivary EGF as a biomarker for OL. Further studies are needed to
elucidate the role of EGF in oral carcinogenesis. A follow-up study is necessary to evaluate the changes in EGF values
following the surgical excision of OL. (Oral Surg Oral Med Oral Pathol Oral Radiol 2015;119:451-458)Oral leukoplakia (OL), a potentially malignant disorder,
is deﬁned as a white plaque of questionable risk that
cannot be clinically or pathologically characterized as
any other disease.1 The rates of malignant transformation
are variable and are inﬂuenced by gender, the clinical
aspects of OL, association with tobacco use, and the
presence of epithelial dysplasia.2,3 Evidence suggests
that tobacco and alcohol use may be associated with at
least a subset of OL cases;4 however, this evidence is
primarily based on the results of observational studies
that report the regression of OL following cessation of
tobacco use.5 There is a lack of reliable markers
associated with the pathogenesis of OL.
Epidermal growth factor (EGF), a 53-amino acid
polypeptide, was originally isolated from mouse salivary
glands. In humans, the major sources of EGF are the pa-
rotid glands and kidneys.6 EGF is a member of a family of
peptide growth factors that activate EGF receptors.
EGF/EGFR signaling pathway plays important roles in
the proliferation, differentiation, and migration of aSome results of this research were presented at the 2014 IAOP
meeting; the abstract title was “EGF in saliva and tissue samples of
oral leukoplakia.”
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as a mitogen, EGF can function both in the maintenance
of epithelial integrity6 and in carcinogenesis.8 The
EGF/EGFR signaling pathway has been implicated in
the pathogenesis of a variety of tumors, including oral
squamous cell carcinoma.9 A recent study suggested that
EGFR represents a sensitive marker to identify the
neoplastic potential of neoplastic tissues.10
The immunohistochemical expression of EGF has
been correlated with tumor progression in the oral
mucosa.11 Some studies have reported lower levels of
EGF in the saliva of patients who smoke12,13
compared with nonsmokers. In previous studies from
our research group, reduced salivary levels of EGF
were identiﬁed in patients with oral squamous cell
carcinoma (OSCC), and this reduction was inﬂuenced
by smoking, tumor location, and alcohol consump-
tion.13,14 Thus, if tobacco use diminishes the EGF
concentration in saliva, the EGF pathway might be
involved in oral carcinogenesis.
On the basis of these considerations, we hypothesized
that salivary EGF could also be reduced in OL, therebyStatement of Clinical Relevance
This pilot study evaluated whether salivary
epidermal growth factor (EGF) could be used as a
biomarker for oral leukoplakia (OL); however, there
was no difference in the levels of EGF in the saliva
of patients and healthy controls.
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carcinogenesis. Therefore, the aims of this study were to
verify the salivary levels of EGF in patients with OL and
to compare these levels with those of healthy individuals.
Furthermore, clinicopathologic features that are consid-
ered risk factors for the malignant transformation of OL,
including the presence or absence of dysplasia, were
compared with the salivary levels and immunoex-
pression of EGF and EGFR in tissues.MATERIALS AND METHODS
Patients
The study protocol was approved by the Ethics Com-
mittee of the Federal University of Minas Gerais
(07330712.5.0000.5149), and all participants signed an
informed consent form. The study was conducted in
compliance with the Helsinki Declaration.
Patients with OL who attended the Oral Medicine
Clinics of the School of Dentistry of the Federal Uni-
versity of Minas Gerais were enrolled in the study (case
group). The case group included patients with newly
diagnosed OL lesions as well as patients who were under
follow-up for previously diagnosed OL and still pre-
sented anOL lesion. Clinical data, including age, gender,
the number and location of lesions, and smoking and
alcohol habits, were recorded during the clinical exami-
nation. Individuals included in the control group were
healthy, had no oral lesions, and were matched with the
case group by gender, age, and smoking habits.15 The
amount of cigarettes used were considered for
matching. In accordance with our previous studies,
individuals were not matched for alcohol consumption
because of the difﬁculty in matching controls with the
same or similar alcohol consumption proﬁles. Patients
and controls with signs of signiﬁcant medical
problems, such as congestive heart failure, active
infection, autoimmune disease, hepatitis, human
immunodeﬁciency virus (HIV) infection, or abnormal
renal function were excluded from the study.14 The
clinical information was correlated with salivary EGF
levels.Saliva and OL tissue samples
Patients refrained from eating, drinking, smoking, and
performing oral hygiene procedures for at least 1 hour
before saliva collection. A cotton wool swab (Salivette,
Sarstedt AG and Co., Numbrecht, Oberbergischer
Kreis, Germany) was placed in the mouth for 5 minutes.
The samples were immediately diluted (1:1) in phos-
phate buffered saline solution that contained protease
inhibitors (0.1 mM phenylmethylsulfonyl ﬂuoride,
0.1 mM benzethonium chloride, 10 mM ethyl-
enediaminetetraacetic acid, and 0.01 mg/mL aprotinin
A) and 0.05% Tween-20. The processed samples werestored at 20C for use in enzyme-linked immuno-
sorbent assay (ELISA).
Hematoxylin-eosin stained sections of formalin-
ﬁxed, parafﬁn-embedded materials from incisional or
excisional lesion biopsies were evaluated and used for
immunohistochemistry. Twenty-six OL samples were
selected and histopathologically classiﬁed into two
groups according to the presence or absence of
epithelial dysplasia, on the basis of the WHO recom-
mendation.2 The tongue and the ﬂoor of the mouth were
considered high-risk sites, whereas all other sites were
considered low risk.3Enzyme-linked immunosorbent assay
Salivary EGF levels were measured via a sandwich
ELISA by using a commercially available kit, Human
EGF (DuoSet, R and D Systems, Minneapolis, MN), in
accordance with the manufacturer’s instructions. The
total protein content in the saliva was determined using
the Bradford method16 (Sigma, St. Louis, MO); bovine
serum albumin was used as the standard (Fermentas
Life Sciences, Vilnius, Lithuania). The total protein
content was used to normalize the EGF values for
each sample.
To investigate the relationship between salivary EGF
levels and categorical variables examined, the median
EGF value in the saliva of the OL patients was estab-
lished (¼ 0.046). The median was used as the cutoff
value to categorize EGF as “low” if the value was equal
to or lower than the median or “high” if it was higher
than the median.Immunohistochemical staining
First, 3-mm sections were deparafﬁnized in xylenes and
hydrated with graded ethanol. Following endogenous
peroxidase blockage, antigen retrieval was performed
with TRIS-EDTA solution, pH 8.0. The specimens were
then incubated with anti-EGF (1:50) and anti-EGFR
(1:100) antibodies (clone EGF-10 [Santa Cruz Biotech-
nology, Inc., Santa Cruz, CA], and clone 31 G7 [Zymed
Laboratories Inc., San Francisco, CA], respectively).
Dako System Advance HRP was then applied (Dako,
Carpinteria, CA, code-k4068). The reaction was revealed
with DAB chromogenic solution and counterstained with
Mayer hematoxylin. Negative controls were obtained by
omitting the primary antibody, and samples of healthy
oral mucosa of known immunoreactivity were included
as positive controls (eg, retromolar mucosa from surgical
excision of included third molars).Immunohistochemical evaluation
Immunohistochemical staining was analyzed by two
observers (MCFA and FJ) who were blinded to the data.
Table I. Clinicopathologic features of the oral leuko-
plakia group
N (%) P value
Gender >.05
Female 14 (43.8)
Male 18 (56.2)
Age (years) >.05
60 14 (43.8)
>60 18 (56.2)
Site* <.05
High risk 06 (18.8)
Low risk 26 (81.2)
Aspects <.05
Homogeneous 25 (78.1)
Heterogeneous 07 (21.9)
Number of lesions >.05
Multiple 21 (65.5)
Single 11 (34.4)
Size >.05
5 mm 05 (15.6)
06e10 mm 14 (43.8)
10e15 mm 01 (03.1)
20 mm 12 (37.5)
Smoking habit >.05
No 18 (56.2)
Yes 14 (43.8)
Alcohol consumption >.05
No 17 (53.1)
Yes 15 (46.9)
Epithelial dysplasiay <.05
Present 07 (21.9)
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observer microscope, and evaluation discrepancies
were resolved by discussing the cases. The expression of
EGF was evaluated by the extent and intensity of
immunolabeling in the cytoplasm.17 The staining
intensity was classiﬁed into ﬁve groups: 0 ¼ no
staining; 1 ¼ weak; 2 ¼ moderate; 3 ¼ strong; and
4 ¼ very strong. The extent of staining was classiﬁed
as follows: 0 ¼ no immunostaining; 1 ¼ less than 25%
of epithelial cells demonstrated positivity; 2 ¼ 25% to
50% of cells demonstrated positivity; 3 ¼ 50% to 75%
of cells demonstrated positivity; and 4 ¼ greater than
75% of cells demonstrated positivity. A ﬁnal score was
established by adding the two indexes. According to
this ﬁnal score, the cases were divided into three
groups: Negative () ¼ score 0; positive (þ) ¼ scores
1 to 4; and strong positive (þþ) ¼ scores 5 to 8.
For EGFR evaluation, the extent and intensity of
immunolabeling in the epithelial cell membranes were
classiﬁed according to a four-point scale:18 0 (no
labeling or labeling in <10% of the cells); 1 (weak
labeling, homogeneous or patchy, in >10% of the
cells); 2 (moderate labeling, homogeneous or patchy,
in >10% of the cells); and 3 (intense labeling,
homogenous or patchy, in >10% of the cells). These
scores were then grouped into two categories:
negative (0 and 1) and positive (2 and 3).Absent 25 (78.1)
*High risk, tongue and/or ﬂoor mouth; low risk, other sites.
yPresent, high-risk; absent, low-risk.Statistical analysis
The statistical analysis was performed with the use of
SPSS software, version 21 (SPSS Inc., Chicago, IL). The
results are expressed as the mean standard deviation. A
Shapiro-Wilk test indicated no normality for EGF
(P < .05). The Wilcoxon test was used to compare the
salivary EGF levels between the controls and the cases. A
one-sample test of proportions was used to make in-
ferences regarding the proportion in each category. The
differences in categorical variables and immunoex-
pression of EGF and EGFR were analyzed by using the
Chi-square and Fisher’s exact tests, when applicable. P
values less than .05 were considered signiﬁcant.RESULTS
Notably, the proportion of patients who smoked
(43.8%) was similar to the proportion of patients who
consumed alcohol (46.9%), and this proﬁle was also
veriﬁed for the controls (53.1% of the patients drank
some alcohol).
Patient information and the clinicopathologic features
of OL are shown in Table I. Most lesions were
homogeneous, classiﬁed as absent dysplasia, and located
in regions of low risk for malignant transformation
(P < .05). Low-risk regions included the alveolar ridge
(n¼ 9), the jugal (cheek) mucosa (n¼ 9), the retromolarregion (n¼ 3), the alveolar mucosa (n¼ 2), and the hard
palate, gingiva, and labialmucosa (1 case each). High-risk
lesions were from the tongue (n ¼ 6). Soft palate and lip
lesions were not included because of different etiologic
factors.Salivary levels of EGF
There was no signiﬁcant difference (P ¼ .254) in the
salivary EGF levels between the patients
(0.059  0.033 pg/mg protein) and the controls
(0.077 0.061 pg/mg protein) (Figure 1). No signiﬁcant
association was identiﬁed between the salivary levels of
EGF and the clinical features examined (Table II). There
was no association between the salivary levels of EGF
and the immunohistochemical expression of EGF or
EGFR.Immunohistochemical expression of EGF
EGFwas positive in 8 (30.8%) and negative in 18 (69.2%)
OL samples (Table III). No sample presented a “strong
positive” score. The pattern of the immunoexpression
was a brown staining in the cytoplasm (Figure 2).
Nuclear EGF expression was observed in 11 (42.3%)
Table II. Association of clinicopathologic features and
salivary levels of EGF
High EGF, N (%) Low EGF, N (%) P
Gender
Female 8 (57.1) 6 (42.9) .476*
Male 8 (44.4) 10 (55.6)
Age (years)
60 6 (42.9) 8 (57.1) .476*
>60 10 (55.6) 8 (44.4)
Site
High risk 2 (33.3) 4 (66.7) .654y
Low risk 14 (53.8) 12 (46.2)
Appearance
Homogeneous 12 (48.0) 13 (52.0) 1.000y
Heterogeneous 4 (57.1) 3 (42.9)
Number of lesions
Multiple 10 (47.6) 11 (52.4) .710*
Single 6 (54.5) 5 (45.5)
Smoking habit
No 11 (61.1) 7 (38.9) .154*
Yes 5 (35.7) 9 (64.3)
Alcohol consumption
No 10 (58.8) 7 (41.2) .288*
Yes 6 (40.0) 9 (60.0)
Epithelial dysplasia
Present 6 (85.7) 1 (14.3) .083y
Absent 10 (40.0) 15 (60.0)
EGF, epidermal growth factor.
*Chi-square test
yFisher’s exact test
Fig. 1. Levels of epidermal growth factor (EGF) in saliva of
patients with oral leukoplakia (case) and healthy patients
(control), expressed as mean  standard deviation. There was
no signiﬁcant difference in the EGF salivary levels between
case (0.059  0.033 pg/mg protein) and control groups
(0.077  0.061 pg/mg protein).
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immunohistochemical evaluation. There was no
signiﬁcant association between the immunoexpression
and salivary levels of EGF (P ¼ .683).
A signiﬁcant association between the number of le-
sions and the immunoexpression of EGF was identiﬁed
(Table IV). Most patients (75%) who presented with a
single lesion had positive staining for EGF, whereaspatients who had multiple lesions (88.9%) had
negative immunoexpression for EGF (P ¼ .003).
There was no signiﬁcant association between EGF
immunoexpression and other clinicopathologic features
(Table IV).Immunohistochemical expression of EGFR
Immunoreactivity of EGFR appeared as a brownish
color in the cytoplasmic membrane of cells and was
detected in 16 (61.5%) cases (Figure 3). Staining was
negative in 38.5% (n ¼ 10) of the cases. There was
no association between EGFR immunoreactivity and
the clinicopathologic variables examined in this study
(P > .05).Histopathologic features
Most OL lesions (78.1%) presented no dysplasia on his-
topathologic assessment. We could not ﬁnd any associa-
tion between salivary levels of EGF and the presence of
dysplasia, although there was a tendency for patients with
dysplasia to have high salivary EGF (P ¼ .083). More-
over, the presence of dysplasia was not associated with
EGF or EGFR immunoexpression (P > .05).DISCUSSION
This study investigated salivary EGF levels and the
expression of EGF and EGFR in tissues obtained from
patients with OL compared with those from healthy
individuals. EGF is a potent mitogen in cells that ex-
press its receptor, EGFR.8 Although EGF plays an
important role in tissue development and homeostasis,
it is also overexpressed in a variety of cancer types
and promotes tumorigenesis and metastasis.19
Interestingly, the ligands of EGFR may only fully
activate the cognate receptors as soluble factors
because ligand-induced conformational changes are
required for receptor dimerization and the generation of
intracellular signals.20 To date, no study has
investigated the association between salivary EGF
levels and OL.
EGF exhibits different expression levels when
detected in varied biologic and pathologic states;21
however, no study has established the normal levels
of salivary EGF in healthy individuals. For this
reason, median values were used in the present and
previous studies13 to categorize the values as “low” or
“high.”
Because this was the ﬁrst study to explore salivary
EGF in patients with OL, calculation of an appropriate
sample size was not feasible. Alternatively, we per-
formed a sample size calculation on the basis of the
prevalence of OL in the population (2%; from a mini-
mum sample of 28 cases).
Table III. Salivary levels and immunoexpression of EGF
Negative immunostaining,
N (%)
Positive immunostaining,
N (%) Total, N (%)
High salivary EGF 9 (75.0) 3 (25.0) 12 (46.2)
Low salivary EGF 9 (64.3) 5 (35.7) 14 (53.8)
Total 18 (69.2) 8 (30.8) 26 (100.0)
EGF, epidermal growth factor.
Fig. 2. Epidermal growth factor (EGF) expression in oral leukoplakia (OL). A, OL from tongue showing hyperkeratosis and no
epithelial dysplasia. This sample was negative for EGF (score 0, no staining). B, OL from tongue, with hyperkeratosis and mild
epithelial dysplasia. This sample illustrates a positive (þ) OL showing a weak staining (score 1 for intensity) in 50% to 75% of cells
(score 3 for extension) (ﬁnal score ¼ 4). C, OL from tongue, with hyperkeratosis and no epithelial dysplasia. This sample illustrates
strongly positive (þþ) expression of EGF. It shows very strong labeling (score 4) in more than 75% of the cells (score 4) (ﬁnal
score ¼ 8). D, OL of the tongue showing no epithelial dysplasia. Moderate nuclear staining can be detected. A high resolution
version of the image is available as eSlide:VM00400.
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with OSCC have lower salivary EGF levels compared
with healthy individuals and that the amount of this
protein is inﬂuenced by certain risk factors, such as
tobacco use.13 Therefore, we hypothesized that salivary
EGF levels could be reduced in OL; however, in our
study, patients with OL had similar EGF levels
compared with controls. We should consider that OL
is a highly heterogeneous disease, with diverse
clinical presentations and histopathologic features that
impact the behavior of OL.22,23 In this preliminary
study, we did not consider these factors in the selection
of the OL samples, although most lesions were homo-
geneous and without atypia. A more homogeneous
sample is recommended for future studies.
Both groups in our study were represented by in-
dividuals approximately 60 years of age. The potential
effect of age in the salivary ﬂux was considered in this
study. The total protein content was used to normalizethe EGF values for each sample, and there was no
difference in the salivary protein content between the
patients (4.152  1.118 mg protein/mL saliva) and the
controls (4.104  2.213 mg protein/mL saliva)
(P ¼ .317).
Despite this limitation, the results of the present study
suggest that diminished salivary EGF levels are observed
only when OSCC is established,14 not in the
premalignant stage. One potential explanation for this
effect is negative feedback: In the early stages of
carcinogenesis, the “normal” EGF levels may
contribute to the molecular and morphologic alterations
observed in OL. Thus, as a regulatory response, EGF
secretion diminishes upon development of OSCC.
However, the effects of EGF in established cancer
should also be associated with the process of ulcer or
wound healing. The downregulation of EGF and its
receptor, as well as the mislocalization of EGFR in the
cytoplasm of keratinocytes instead of at the membrane,
Table IV. Association of clinicopathologic features
and immunoexpression of EGF
Negative, N (%) Positive, N (%) P
Gender
Female 8 (66.7) 4 (33.3) 1.000*
Male 10 (71.4) 4 (28.6)
Age (years)
 60 10 (90.9) 1 (9.1) .084*
> 60 8 (53.3) 7 (46.7)
Site
High risk 2 (33.3) 4 (66.7) .051y
Low risk 16 (80.0) 4 (20.0)
Aspects
Homogeneous 14 (66.7) 7 (33.3) 1.000*
Heterogenous 4 (80.0) 1 (20.0)
Number of lesions
Multiple 16 (88.9) 2 (11.1) .003y
Single 2 (25.0) 6 (75.0)
Smoking habit
No 10 (66.7) 5 (33.3) 1.000*
Yes 8 (72.7) 3 (27.3)
Alcohol consumption
No 8 (66.7) 4 (33.3) 1.000*
Yes 10 (71.4) 4 (28.6)
Epithelial dysplasiaz
Present 4 (66.7) 2 (33.3) 1.000*
Absent 14 (70.0) 6 (30.0)
*Chi-square test.
yFisher’s exact test.
zPresent, high-risk; absent, low-risk.
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ulcers). Moreover, exogenous EGF is readily degraded
in the chronic wound environment.24 These ﬁndings
may explain the low levels of EGF that are observed
in oral cancer but not in OL.
Another point to consider is that EGF effects are
triggered in the cell only if it is properly bound to
EGFR. It is known that the expression of a high number
of receptors or truncated receptors on tumor cells can
increase the sensitivity to low concentrations of growth
factors.25 Accordingly, genetic alterations have been
identiﬁed in EGFR genes in human cancers.26-28
Thus, if OL cells have abnormal EGFR expression or
function, they could overrespond to normal EGF levels.
In accordance with this hypothesis, Ribeiro et al.29
demonstrated that EGFR immunoreactivity is
common in OL, especially in high-risk lesions.
Mahendra et al.10 also described high EGFR expression
in dysplastic lesions.
In the present study, we could not identify a relation-
ship between salivary EGF and EGFR or EGF tissue
expression. Surprisingly, Bernardes et al.30 demonstrated
that EGFR expression was not dependent on the gene
copy number in OSCC. Metha et al.28 and Tushar and
Ramanathan31 did not identify mutations in the EGFR
gene in OSCC. This issue should be clariﬁed in futuregenetic studies of EGFR in OL. However, the tissue
overexpression of EGF could be insufﬁcient for the
autostimulation of cancer progression until ectodomain
shedding occurs, which is a process dependent on A
disintegrin and metalloprotease (ADAM) proteins.20
Thus, the EGF expressed in epithelial cells is not
necessarily delivered to the saliva.
In the carcinogenic process, epithelial and mesen-
chymal tissues continuously interact via secreted mol-
ecules. In this milieu, inﬂammation may play a crucial
role in the stimulation of dysplastic alterations or the
protection of the host against them.32-34 In line with this
role, EGF can synergistically enhance the production of
interleukin-8 in human gingival ﬁbroblasts,35 increase
matrix metalloproteinase 1 (MMP-1) and MMP-3 pro-
duction in these cells,36 and regulate the expression of
genes involved in inﬂammation and cancer.37
Interestingly, Chang et al.38 suggested that
inﬂammation activates the binding capacity of EGF in
the gingiva, and the upregulation of EGFR in
inﬂamed gingiva may be associated with a lower EGF
concentration in the gingival crevicular ﬂuid. Thus, it
appears important to explore the relationship between
inﬂammation and EGF in OL and OSCC.
No signiﬁcant association was identiﬁed between the
salivary levels of EGF and the clinical features of OL.
Importantly, some features (female gender, location in
the ﬂoor of the mouth and the tongue, size >200 mm,
heterogeneous type, and presence of epithelial
dysplasia) have been associated with lesions with a
worse prognosis.39 Thus, we can infer that salivary
EGF cannot be regarded as an indicator of high-risk
OL at this point. Leukoplakia is a clinical term, which
is not associated with a speciﬁc histopathologic diag-
nosis. Nevertheless, there was a tendency for patients
with OL lesions with dysplasia to present with high
salivary EGF (P ¼ .083), which is regarded as the most
important feature related to OL prognosis. This hy-
pothesis should be conﬁrmed in further follow-up
studies with larger sample sizes or in animal models
of oral carcinogenesis. These studies would clarify
whether EGF contributes to the evolution of OL,
thereby favoring cancer development.
An association was identiﬁed between the number of
lesions and tissue EGF levels, but at this point, this
association cannot be explained. An evaluation of all
lesions is necessary to conﬁrm this result, and the bi-
opsy of multiple areas within one lesion tipically yields
small specimens.
Nuclear EGF immunolabeling was observed and was
considered positive in 34.6% of cases and strongly pos-
itive in 7.7%. Accumulating evidence suggests that the
nucleus is a second site of cellular EGF action. This
evidence has been demonstrated by the presence of
EGF and EGFR in various types of tissues, including
Fig. 3. Epidermal growth factor receptor (EGFR) expression in oral leukoplakia (OL). A, OL from retromolar region showing
hyperkeratosis and mild dysplasia. This specimen shows a weak homogeneous labeling in >10% of the cells (score 1), thus set as
negative. B, Closer caption of A. Note the weak and homogeneous membranous staining in keratinocytes mainly in the spinous
layer. C, OL from jugal mucosa showing hyperkeratosis and no dysplasia. This sample shows an intense homogenous labeling in
>10% of the cells (score 3), thus classiﬁed as positive. A high resolution version of the image is available as eSlide: VM00399.
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its receptor were found not only in association with the
cell membrane but also in the cytoplasm and nuclei of
all thyroid tissues investigated. This same pattern was
identiﬁed in OL, indicating the need for further
investigation to elucidate the relationship between the
nuclear staining of EGF and the pathogenesis of OL. A
membranous distribution of EGFR was observed in
61.5% of cases; this is consistent with the normal
location of this receptor.CONCLUSIONS
Salivary EGF levels in patients with OL do not differ
from those in healthy individuals despite the impor-
tance of EGF and EGFR in neoplasia. Salivary levels
of EGF were not associated with tissue EGF either.
So, at this moment, it is not possible to recommend
the use of salivary EGF as a biomarker of leukopla-
kia. Further studies are needed to elucidate the role of
EGF in oral carcinogenesis and to assess possible
changes in EGF values following the surgical exci-
sion of OL.
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